🔥🐔 BizChicken 🐔🔥
Companies Similar to Candel Therapeutics, Inc.
Sign Up Today!
Sign up for BizChicken and discover more about the corporations around you.
Candel Therapeutics, Inc.
CAN-2409, CAN-3110
Candel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing immunotherapies for cancer patients, with products like CAN-2409 and CAN-3110 in various clinical trial phases.
About | About | About | About | Contact | Careers | Careers | About | About | About | Careers | About
Symbol: CADL
Recent Price: $7.95
Industry: Biotechnology
CEO: Dr. Paul-Peter Tak FOCIS, M.D., Ph.D.
Sector: Healthcare
Employees: 42
Address: 117 Kendrick Street, Needham, MA 02494
Phone: 617 916 5445
Last updated: 2024-12-31
CERo Therapeutics Holdings, Inc.
Engineered T Cell Therapeutics
CERo Therapeutics Holdings, Inc. is an immunotherapy company focused on developing engineered T cell therapeutics for cancer treatment, particularly targeting hematologic malignancies using innovative immune system integration strategies.
Symbol: CERO
Recent Price: $0.06
Industry: Biotechnology
CEO: Mr. Christopher B. Ehrlich M.B.A.
Sector: Healthcare
Employees: 8
Address: 201 Haskins Way, South San Francisco, CA 94080
Phone: 650-407-2376
Last updated: 2024-12-31
Elicio Therapeutics, Inc.
ELI-002
Elicio Therapeutics is a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for cancer and other diseases, with its lead product ELI-002 targeting KRAS-driven cancers.
Symbol: ELTX
Recent Price: $5.00
Industry: Biotechnology
CEO: Mr. Robert T. Connelly
Sector: Healthcare
Employees: 32
Address: 451 D Street, Boston, MA 02210
Phone: 857-209-0050
Last updated: 2024-12-31
Fate Therapeutics, Inc.
programmed cellular immunotherapies
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its development programs include various NK- and T-cell immuno-oncology therapies targeting different cancers.
Vision/Values | About | Management | Directors | About | Contact
Symbol: FATE
Recent Price: $1.62
Industry: Biotechnology
CEO: Mr. J. Scott Wolchko
Sector: Healthcare
Employees: 181
Address: 12278 Scripps Summit Drive, San Diego, CA 92131
Phone: 858 875 1800
Leadership
- William Rastetter, Ph.D., Chairman
- John Mendlein, Ph.D., J.D., Vice Chairman
- Dr. Shefali Agarwal, Board Member
- Timothy P. Coughlin, Board Member
- Robert S. Epstein, M.D., Board Member
- Karin Jooss, Ph.D., Board Member
- Michael Lee, Board Member
- Neely Mozaffarian, M.D., Ph.D., FACR, Board Member
- Yuan Xu, Ph.D., Board Member
- Scott Wolchko, President & CEO
Last updated: 2024-12-31
Oncternal Therapeutics, Inc.
zilovertamab, ONCT-216, ONCT-808, ONCT-534
Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in oncology therapies for cancers with significant unmet medical needs, featuring a pipeline that includes the monoclonal antibody zilovertamab and various other targeted treatments.
Symbol: ONCT
Recent Price: $0.53
Industry: Biotechnology
CEO: Dr. James B. Breitmeyer M.D., Ph.D.
Sector: Healthcare
Employees: 27
Address: 12230 El Camino Real, San Diego, CA 92130
Phone: 858 434 1113
Last updated: 2024-12-31
Pyxis Oncology, Inc.
PYX-106, PYX-102, PYX-201, PYX-202, PYX-203
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, focuses on developing therapies to treat various cancers through immune-oncology and antibody drug conjugate product candidates.
Symbol: PYXS
Recent Price: $1.56
Industry: Biotechnology
CEO: Dr. Lara S. Sullivan M.D., MBA
Sector: Healthcare
Employees: 55
Address: 35 Cambridgepark Drive, Cambridge, MA 02140
Phone: 617 221 9059
Last updated: 2024-12-31
Zentalis Pharmaceuticals, Inc.
ZN-c3, ZN-c5
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for treating various cancers. Its leading product candidates include ZN-c3 and ZN-c5, which are in various phases of clinical trials targeting specific cancer types.
About | About | Contact | Contact | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | About | About
Symbol: ZNTL
Recent Price: $2.92
Industry: Biotechnology
CEO: Dr. Kimberly Lynn Blackwell M.D.
Sector: Healthcare
Employees: 124
Address: 1359 Broadway, New York, NY 10018
Phone: 212 433 3791
Last updated: 2024-12-31
C4 Therapeutics, Inc.
CFT7455
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Their lead product candidate, CFT7455, targets multiple myeloma and non-Hodgkin lymphomas.
Symbol: CCCC
Recent Price: $3.64
Industry: Biotechnology
CEO: Mr. Andrew J. Hirsch M.B.A.
Sector: Healthcare
Employees: 145
Address: 490 Arsenal Way, Watertown, MA 02472
Phone: 617 231 0700
Leadership
- Kendra Adams, Chief Financial Officer
- Scott Boyle, Ph.D., Chief Business Officer
- Stew Fisher, Ph.D., Chief Scientific Officer
- Len Reyno, M.D., Chief Medical Officer
- Jolie Siegel, Chief Legal Officer
- Kelly Schick, Chief People Officer
- Mary Christian, Pharm. D., Senior Vice President, Regulatory
- Mayra Reyes-Armour, Ph.D., Senior Vice President, Technical Operations, Quality and Facilities
- Ron Cooper, Chairman
- Ken Anderson, M.D., Director
- Laura Bessen, M.D., Director
- Bruce Downey, Director
- Stephen Fawell, Ph.D., Director
- Donna Grogan, M.D., Director
- Andrew Hirsch, President and Chief Executive Officer, Director
- Owen Hughes, Director
- Utpal Koppikar, Director
- Marc Cohen, In MemoriamCo-Founder & Executive Chairman Emeritus
Last updated: 2024-12-31
Celularity Inc.
CYCART-19, CYNK-001, CYNK-101, APPL-001, PDA-002
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and Bio Banking.
About | Leadership | Directors | About | About | About | About | Directors | Careers | About | About | About | About | About | About
Symbol: CELU
Recent Price: $2.05
Industry: Biotechnology
CEO: Dr. Robert Joseph Hariri M.D., Ph.D.
Sector: Healthcare
Employees: 120
Address: 170 Park Avenue, Florham Park, NJ 07932
Phone: 908 768 2170
Leadership
- Robert J. Hariri, M.D., Ph.D., Chairperson, Founder, and CEO
- David Beers, CFA, Chief Financial Officer
- Stephen Brigido, DPM, President, Degenerative Diseases
- John Haines, Global Manager and Chief Administrative Officer
- K. Harold Fletcher, Esq., General Counsel & Chief Compliance Officer
- John Colerangle, DVM, Ph.D., Regulatory Affairs
- Anna Gosiewska, Ph.D., R&D, Degenerative Diseases
- Sharmila Koppisetti, M.D., Clinical Development Immunology & Drug Safety
- Carmine Palummo, Corporate Operations
- Tim Wilk, Technical Operations
- Robert J. Hariri, M.D., Ph.D, Chairperson, Founder & CEO
- Peter Diamandis, M.D., Director
- Dean Kehler, Director
- Geoffrey Shiu Fei Ling, M.D., Ph.D., Director
- Diane Parks, Director
Last updated: 2024-12-31
Checkpoint Therapeutics, Inc.
Cosibelimab
Checkpoint Therapeutics, Inc. is a clinical-stage immunotherapy and targeted oncology company focused on acquiring, developing, and commercializing novel treatments for solid tumor cancers. Their lead product candidates include Cosibelimab, a fully-human monoclonal antibody, and other treatments for various cancer targets.
Symbol: CKPT
Recent Price: $3.35
Industry: Biotechnology
CEO: Mr. James F. Oliviero III, C.F.A.
Sector: Healthcare
Employees: 23
Address: 95 Sawyer Road, Waltham, MA 02453
Phone: 781 652 4500
Last updated: 2024-12-31
Celldex Therapeutics, Inc.
therapeutic monoclonal and bispecific antibodies
Celldex Therapeutics is a biopharmaceutical company focused on developing therapeutic monoclonal and bispecific antibodies for treating inflammatory diseases and cancers.
About | About | Management | Directors | About | Contact | About | Contact | Careers | Careers | Careers | Careers | Jobs | Careers | About | About
Symbol: CLDX
Recent Price: $25.12
Industry: Biotechnology
CEO: Mr. Anthony S. Marucci M.B.A.
Sector: Healthcare
Employees: 160
Address: Perryville III Building, Hampton, NJ 08827
Phone: 908 200 7500
Leadership
- Anthony S. Marucci, Founder, President, Chief Executive Officer and Director
- Tibor Keler, Ph.D., Founder, Executive Vice President and Chief Scientific Officer
- Diane C. Young, M.D., Senior Vice President and Chief Medical Officer
- Elizabeth Crowley, Senior Vice President, Chief Product Development Officer
- Sam Martin, Senior Vice President and Chief Financial Officer
- Ronald A. Pepin, Ph.D., Senior Vice President and Chief Business Officer
- Richard Wright, Ph.D., Senior Vice President and Chief Commercial Officer
- Sarah Cavanaugh, Senior Vice President, Corporate Affairs and Administration
- Margo Heath-Chiozzi, M.D., Senior Vice President, Regulatory Affairs
- Freddy A. Jimenez, Esq., Senior Vice President and General Counsel
- Karen L. Shoos, J.D., Former Chair, Director of Operations, Maryland Tech Council Venture Mentoring Services Program
- Keith L. Brownlie, Former Partner, Ernst & Young LLP
- Herbert J. Conrad, Former President, Roche Pharmaceuticals US
- James J. Marino, J.D., Former Partner, Dechert LLP
- Harry H. Penner, Jr., J.D., L.L.M., Former Chairman and CEO, Nascent Bioscience
- Cheryl L. Cohen, President, CLC Consulting; Former Chief Commercial Officer of Medivation, Inc.
- Dr. Garry Neil, Chief Executive Officer; Chair of the Board, Avalo Therapeutics
- Rita Jain, M.D., Former Executive Vice President, Chief Medical Officer of ChemoCentryx, Inc.
- Carl June, M.D.,
- Michel Nussenzweig, M.D., Ph.D.,
- Marc E. Rothenberg M.D., Ph.D.,
- Joseph Schlessinger, Ph.D.,
- Louis Weiner, M.D.,
Last updated: 2024-12-31
Compass Therapeutics, Inc.
CTX-009, CTX-471, CTX-8371
Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing antibody-based therapeutics to treat various human diseases. Their clinical stage products include investigational bispecific antibodies like CTX-009 and monoclonal antibodies such as CTX-471.
Symbol: CMPX
Recent Price: $1.48
Industry: Biotechnology
CEO: Dr. Thomas J. Schuetz M.D., Ph.D.
Sector: Healthcare
Employees: 32
Address: 80 Guest Street, Boston, MA 02135
Phone: 617 500 8099
Last updated: 2024-12-31
Immuneering Corporation
IMM-1-104 and IMM-6-415
Immuneering Corporation is a biopharmaceutical company focused on developing oncology and neuroscience product candidates, with key products like IMM-1-104 for cancer treatment and IMM-6-415 for solid tumors.
Symbol: IMRX
Recent Price: $2.25
Industry: Biotechnology
CEO: Dr. Benjamin J. Zeskind M.B.A., Ph.D.
Sector: Healthcare
Employees: 66
Address: 245 Main Street, Cambridge, MA 02142
Phone: 617 500 8080
Last updated: 2024-12-31
Indaptus Therapeutics, Inc.
Decoy20
Indaptus Therapeutics, Inc. is a pre-clinical biotechnology company focusing on the development of anti-cancer and anti-viral immunotherapy products, with its lead clinical candidate, Decoy20, targeting lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as viral infections.
Symbol: INDP
Recent Price: $0.87
Industry: Biotechnology
CEO: Mr. Jeffrey A. Meckler
Sector: Healthcare
Employees: 7
Address: 3 Columbus Circle, New York, NY 10019
Phone: 347 480 9760
Last updated: 2024-12-31
Intensity Therapeutics, Inc.
INT230-6
Intensity Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of cancer drugs for treating solid tumors. Their lead product, INT230-6, is undergoing Phase 2 trials for various cancers and is being tested in collaborations with major pharmaceutical companies.
Symbol: INTS
Recent Price: $1.82
Industry: Biotechnology
CEO: Mr. Lewis H. Bender M.A., M.B.A., M.S.
Sector: Healthcare
Employees: 5
Address: 61 Wilton Road, Westport, CT 06880
Phone: 203 221 7381
Leadership
- Lewis H. Bender, M.S., M.A., M.B.A., Founder and CEO
- Joseph Talamo, CPA, Chief Financial Officer
- James M. Ahlers, Executive Vice President
- Brian Schwartz, MD, Executive VP, Clinical Development
- John Wesolowski, CPA, MBA, Principal Accounting Officer and Controller
- Kimberly A. Guedes, RN, MBA, Vice President of Clinical Operations
- Doranne Frano, Regulatory Affairs and Quality Control
- Daniel J. Donovan, Board Member and Chief Executive Officer
- Tom Dubin, Board Member
- Mark A. Goldberg, MD, Board Member
- Emer Leahy, Ph.D., Board Member
Last updated: 2024-12-31
MEI Pharma, Inc.
Zandelisib
MEI Pharma, Inc. is a late-stage pharmaceutical company focused on developing and commercializing therapies for cancer treatment, including Zandelisib and Voruciclib.
About | About | About | Contact | Contact | Careers | Careers | Contact | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Site Map | Careers | Careers | Careers | About | About | About | About | About | Jobs | About
Symbol: MEIP
Recent Price: $2.45
Industry: Biotechnology
CEO: Mr. Justin J. File
Sector: Healthcare
Employees: 28
Address: 11455 El Camino Real, San Diego, CA 92130
Phone: 858 369 7100
Last updated: 2024-12-31
TRACON Pharmaceuticals, Inc.
therapeutics for cancer
TRACON Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing cancer therapeutics, including clinical stage products like envafolimab, YH001, TRC102, and TJ004309, with collaboration agreements with various biopharmaceutical companies.
Symbol: TCON
Recent Price: $0.03
Industry: Biotechnology
CEO: Mr. Craig R. Jalbert CIRA
Sector: Healthcare
Employees: 17
Address: 4350 La Jolla Village Drive, San Diego, CA 92122
Phone: 858 550 0780
Last updated: 2024-12-31
Xilio Therapeutics, Inc.
XTX101
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients with a focus on tumor-selective therapies.
Symbol: XLO
Recent Price: $0.97
Industry: Biotechnology
CEO: Dr. Rene Russo BCPS, Pharm.D.
Sector: Healthcare
Employees: 73
Address: 828 Winter Street, Waltham, MA 02451
Phone: 617 430 4680
Last updated: 2024-12-31
Cullinan Oncology, Inc.
CLN-081
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. Their lead candidate, CLN-081, is in a trial for treating non-small cell lung cancer. The company also has several preclinical products targeting various forms of cancer.
Symbol: CGEM
Recent Price: $12.20
Industry: Biotechnology
CEO: Mr. Nadim Ahmed
Sector: Healthcare
Employees: 85
Address: One Main Street, Cambridge, MA 02142
Phone: 617 410 4650
Last updated: 2024-12-31
Tango Therapeutics, Inc.
TNG908
Tango Therapeutics, Inc. is a biotechnology company focused on discovering and developing drugs for cancer treatment, with a lead program TNG908 targeting cancers with methylthioadenosine phosphorylase deletions. The company also works on therapies for BRCA1/2-mutant and STK11-mutant cancers and collaborates with Gilead Sciences, Inc.
Symbol: TNGX
Recent Price: $3.10
Industry: Biotechnology
CEO: Dr. Barbara L. Weber M.D.
Sector: Healthcare
Employees: 140
Address: 100 Binney Street, Cambridge, MA 02142
Phone: 857 320 4900
Last updated: 2024-12-31